Predicted protein targets (top 14)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | L3MBTL1 | Q9Y468 | 2/20 | 0.41 |
| ▸ | RAB9A | P51151 | 4/20 | 0.38 |
| ▸ | NPC1 | O15118 | 2/20 | 0.38 |
| ▸ | ALDH1A1 | P00352 | 2/20 | 0.38 |
| ▸ | NPSR1 | Q6W5P4 | 1/20 | 0.38 |
| ▸ | USP30 | Q70CQ3 | 1/20 | 0.36 |
| ▸ | SMN1; SMN2 | Q16637 | 1/20 | 0.35 |
| ▸ | PTK2 | Q05397 | 1/20 | 0.35 |
| ▸ | F10 | P00742 | 3/20 | 0.34 |
| ▸ | F2 | P00734 | 1/20 | 0.34 |
| ▸ | F5 | P12259 | 1/20 | 0.34 |
| ▸ | MAPT | P10636 | 2/20 | 0.34 |
| ▸ | IDO1 | P14902 | 2/20 | 0.34 |
| ▸ | TDO2 | P48775 | 1/20 | 0.34 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL368516 | 0.91 | L3MBTL1 (0.43) | L3MBTL1RAB9ANPC1ALDH1A1NPSR1 | |
| SCHEMBL715127 | 0.91 | L3MBTL1 (0.43) | L3MBTL1RAB9ANPC1ALDH1A1NPSR1 | |
| SCHEMBL4268700 | 0.90 | L3MBTL1 (0.41) | L3MBTL1RAB9ANPC1ALDH1A1NPSR1 | |
| SCHEMBL4955372 | 0.89 | L3MBTL1 (0.44) | L3MBTL1RAB9ANPC1ALDH1A1NPSR1 | |
| SCHEMBL4267279 | 0.88 | L3MBTL1 (0.43) | L3MBTL1RAB9ANPC1ALDH1A1NPSR1 | |
| SCHEMBL4260523 | 0.87 | L3MBTL1 (0.41) | L3MBTL1RAB9ANPC1ALDH1A1NPSR1 | |
| SCHEMBL3309223 | 0.84 | L3MBTL1 (0.41) | L3MBTL1RAB9ANPC1ALDH1A1NPSR1 | |
| SCHEMBL3306854 | 0.83 | USP30 (0.41) | L3MBTL1RAB9ANPC1ALDH1A1NPSR1 | |
| SCHEMBL3307770 | 0.81 | L3MBTL1 (0.38) | L3MBTL1RAB9ANPC1ALDH1A1NPSR1 | |
| SCHEMBL3306039 | 0.81 | L3MBTL1 (0.38) | L3MBTL1RAB9ANPC1ALDH1A1NPSR1 |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 1 patent. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| US-20090281074-A1 | DRUG COMPOSITIONS AND METHODS FOR PREVENTING AND TREATING THROMBOSIS OR EMBOLISM | DAIICHI PHARMACEUTICAL CO., LTD (JP) | 2009-11-12 | — | — | US | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (1 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20090281074-A1 | DRUG COMPOSITIONS AND METHODS FOR PREVENTING AND TREATING THROMBOSIS OR EMBOLISM | C1R, C9, F2 | L3MBTL1 1605/4885RAB9A 1678/4885NPC1 3934/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.